Chengdu Hoist High-Tech

Haisike Pharmaceutical Group, often operating through its core subsidiary Chengdu Hoist High-Tech, is a prominent Chinese biopharmaceutical company specializing in the development and commercialization of innovative small molecule drugs and high-end generics. The company has established a leading position in the Chinese market for clinical nutrition and anesthesia, notably with the successful launch of Ciprofol (HSK3486), a novel sedative-hypnotic agent. Haisike's R&D pipeline is diverse, targeting significant unmet needs in perioperative care, chronic pain management, and metabolic diseases such as type 2 diabetes. Beyond traditional small molecules, the company is an early adopter of PROTAC technology, advancing candidates like HSK29116 for oncology indications. With integrated manufacturing capabilities and a robust commercial infrastructure, Haisike continues to expand its footprint both domestically and in international markets.